If PPHM did not threaten to go it alone then shareholders should be really upset! Otherwise potential partners would think they could partner or buy it out for fire-sale prices!
PPHM has three very strong cards to play in the partnering poker game.
* One is that they have the patents, the technological know-how, indeed even the manufacturing know-how, AND the finances, to go it alone.
* The second strong card is that immunotherapy is now a very hot item in the oncology world. It is the flavour of the month.
* And the third strong card is that there are several BP's who are interested in partnering/buyout. There are many BP's who desperately need a new oncology platform!
I don't know about anyone else...but in my limited poker experience...holding three aces will result in a very good outcome!
News 
Market Data 
Discover 
AI
